Prognosis and Therapies in Non-Clear Cell Renal Cell Carcinomas
Trilok Shrivastava, Yusra Medik, Nikhila Sampath Kumar, Shi-Ming Tu, Anuradha Kunthur · 2026
Read Prognosis and Therapies in Non-Clear Cell Renal Cell Carcinomas by Trilok Shrivastava, Yusra Medik, Nikhila Sampath Kumar, Shi-Ming Tu, Anuradha Kunthur (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13663911.txt.
Description
Trilok Shrivastava and co-authors review non-clear cell kidney cancers in this 2026 paper. These cancers form a mixed family with distinct drivers and behavior. Lumping them together can hide big gaps in outlook and drug response.
The team analyzed survival by subtype in a national registry with about forty-four thousand adults. Follow-up stretched to a median of eight years. Chromophobe tumors fared better than papillary ones, while collecting duct and medullary types fared far worse. Drugs aimed at blood vessel growth or the MET pathway help some subtypes. Immune checkpoint pairs also show subtype-linked activity. The authors urge trials built per subtype.
Catalog record
| CREATOR | Trilok Shrivastava, Yusra Medik, Nikhila Sampath Kumar, Shi-Ming Tu, Anuradha Kunthur |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |